Drug Trial Radar · NCT05573126
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
95
Planned (sponsor's estimate)
Start
Jan 11, 2023
Primary completion
Feb 2028
Study completion Feb 2028
Sponsor
- Lead sponsor
- Ellipses PharmaIndustry
- Sponsor type
- Industry
- First posted
- Oct 10, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to identify the optimal dose for EP0062 as monotherapy and in combination with standard-of-care therapies to assess its Safety, Tolerability, Pharmacokinetics, and Efficacy in Patients with Relapsed Locally Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Conditions
- Hormone Receptor-positive Breast Cancer
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- Metastatic Breast Cancer
Interventions
EP0062Drug
EP0062 is an orally administered investigational selective androgen receptor modulator (SARM)
ElacestrantDrug
Oral SERD
EverolimusDrug
mTOR Inhibitor
AbemaciclibDrug
CDK4/6 inhibitor
FulvestrantDrug
Oral SERD
ExemestaneDrug
aromatase inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose-limiting toxicities (DLTs) during Cycle 1 of EP0062 treatmentTime frame: first 28 days
- Maximum tolerated dose (MTD) and doses for evaluation in the expansion cohortsTime frame: 1 year
- Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)Time frame: up to 30 days after the end of treatment
- Recommended clinical (dose (s) for combination therapyTime frame: 1 year
Locations
14 sites in 3 countries. Site status is shown where the registry gives one.
Yale School of Medicine
New Haven, Connecticut · Completed
Moffitt Cancer Center
Tampa, Florida · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Henry Ford Hospital
Detroit, Michigan · Recruiting
Sarah Cannon Research Institute
Nashville, Tennessee · Recruiting
Texas Oncology Baylor University Medical Center
Dallas, Texas · Recruiting
Virginia Cancer Specialists
Fairfax, Virginia · Recruiting
Hospital Universitari Vall d'Hebron (VHIO)
Barcelona, Spain · Recruiting
Hospital Universitario Ramón y Cajal
Madrid, Spain · Recruiting
NEXT Oncology Hospital Quironsalud
Madrid, Spain · Recruiting
Hospital 12 de Octubre
Usera, Madrid, Spain · Recruiting
The Clatterbridge Cancer Centre
Liverpool, United Kingdom · Recruiting
Sarah Cannon Research Institute UK
London, London, United Kingdom · Recruiting
The Christie NHS Foundation Trust
Manchester, Wilmslow Rd, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.